Celanese Corporation, a global specialty materials and chemical company, announced the launch of iDose TR by Glaukos Corporation using Celanese’s VitalDose EVA to provide sustained drug release for the treatment of glaucoma.

The majority of glaucoma and ocular hypertension patients are non-compliant with topical medication use due to complex dosing regiments, side effects, and eye-drop intolerance. Sustained delivery of therapeutics provides an important approach in addressing non-compliance and improving treatment outcomes. With iDose TR and the VitalDose EVA, there is now the opportunity to provide continuous dosing which can improve patient compliance and address adherence issues.

iDose TR was approved by the Food and Drug Administration (FDA) in December 2023 and is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. iDose® TR was approved on the basis of two pivotal trials (1,150 subjects randomized across both trials), which demonstrated safety and efficacy.

Glaukos used the VitalDose EVA to create a nanoporous membrane for travoprost delivery in iDose TR. The VitalDose EVA is a platform that can be formulated into a wide range of form factors to suit drug delivery needs for various conditions.

“A clear unmet need exists in ophthalmology for therapies that address non-compliance and reduce the treatment burden for patients,” says Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese. “Our team is excited to support Glaukos as they transform the landscape of glaucoma treatment for millions of patients.”